Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.79 |
| ▸ | POLB | P06746 | 8/20 | 0.79 |
| ▸ | MEN1 | O00255 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743104 | 1.00 | KMT2A (0.79) | KMT2APOLBMEN1RAB9ANPC1 | |
| Phosphoric Acid SCHEMBL30133704 | 0.96 | KMT2A (0.73) | KMT2APOLBMEN1RAB9ANPC1 | |
| Phosphoric Acid SCHEMBL8647709 | 0.96 | KMT2A (0.73) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL29372498 | 0.87 | POLB (0.72) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL30516994 | 0.87 | POLB (0.72) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL1344307 | 0.87 | POLB (0.72) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL7160216 | 0.87 | POLB (0.61) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL825861 | 0.86 | POLB (0.81) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL10340630 | 0.85 | KMT2A (0.67) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL29644311 | 0.85 | KMT2A (0.67) | KMT2APOLBMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085618-A1 | METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION | YYZ PHARMATECH INC. (CA) | 2026-04-30 | — | — | WO | claimed |
| CN-119954692-A | Preparation method of dimethylaniline blue I | 河北百灵威超精细材料有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-20240011108-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ PHARMATECH INC. (CA) | 2024-01-11 | — | — | US | claimed |
| EP-4232598-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ Pharmatech Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| CN-116391047-A | Mass spectrometry-based methods and kits for nucleic acid detection and disease diagnosis | YYZ医药科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| WO-2022087730-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ PHARMATECH INC. (CA) | 2022-05-05 | — | — | WO | claimed |
| CN-117223679-B | Transgenic animal model and construction method and application thereof | 中国科学院深圳先进技术研究院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260097084-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CBFbeta-EXPRESSING VASCULAR SMOOTH MUSCLE CELLS OR CULTURE FLUID THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AGE-RELATED DISEASES | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-04-09 | — | — | US | disclosed |
| US-20260091001-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 4-HEXYLRESORCINOL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF BONE DISEASE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-04-02 | — | — | US | disclosed |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | UNIVERSITY OF ROCHESTER (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3724238-B1 | HEPARAN SULPHATE OLIGOSACCHARIDES FOR USE IN WOUND HEALING | AGENCY SCIENCE TECH & RES (SG) | 2026-03-04 | — | — | EP | disclosed |
| US-20260028624-A1 | AAV-MEDIATED DELIVERY OF OSTEOBLAST/OSTEOCLAST-REGULATING MIRNAS FOR OSTEOPOROSIS THERAPY | UNIVERSITY OF MASSACHUSETTS (US) | 2026-01-29 | — | — | US | disclosed |
| US-12508237-B2 | Pharmaceutical composition comprising 4-hexylresorcinol as active ingredient for prevention or treatment of bone disease | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-12-30 | — | — | US | disclosed |
| WO-2022087730-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ PHARMATECH INC. (CA) | 2022-05-05 | — | — | WO | disclosed |
| US-11305035-B2 | Tissue-derived tissuegenic implants, and methods of fabricating and using same | Musculoskeletal Transplant Foundatiaon (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220111120-A1 | TISSUE-DERIVED TISSUEGENIC IMPLANTS, AND METHODS OF FABRICATING AND USING SAME | M&T BANK | 2022-04-14 | — | — | US | disclosed |
| US-20220071972-A1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2022-03-10 | — | — | US | disclosed |
| CN-109916691-B | Reagent for cell esterase staining | 迈克生物股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20220032289-A1 | Robotic method for coating a multiwell plate by a polyelectrolyte multilayer film | INST POLYTECHNIQUE GRENOBLE (FR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033412-A1 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | NOVARTIS AG (CH) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033412-A1 | 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | COL2A1, COL1A1, HCAR1 | KMT2A 2850/4885POLB 3386/4885MEN1 4723/4885 |
| US-12508237-B2 | Pharmaceutical composition comprising 4-hexylresorcinol as active ingredient for prevention or treatment of bone disease | COL2A1, HKDC1, PLIN1 | KMT2A 2622/4885POLB 3886/4885MEN1 4859/4885 |
| US-20260028624-A1 | AAV-MEDIATED DELIVERY OF OSTEOBLAST/OSTEOCLAST-REGULATING MIRNAS FOR OSTEOPOROSIS THERAPY | CALCRL, PPP4R3A, CALCB | KMT2A 966/4885POLB 2870/4885MEN1 3490/4885 |
| US-20260097084-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CBFbeta-EXPRESSING VASCULAR SMOOTH MUSCLE CELLS OR CULTURE FLUID THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AGE-RELATED DISEASES | CBFB, SREBF1, CALCA | KMT2A 3093/4885POLB 1843/4885MEN1 4471/4885 |
| US-20260091001-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 4-HEXYLRESORCINOL AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF BONE DISEASE | HKDC1, FABP4, ADIPOR1 | KMT2A 1035/4885POLB 4479/4885MEN1 4721/4885 |
| US-20220071972-A1 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | COL2A1, COL1A1, FGF1 | KMT2A 3685/4885POLB 2998/4885MEN1 4744/4885 |
| US-20260069610-A1 | INHIBITION OF EFFEROCYTOSIS AS A TREATMENT TO PREVENT BONE LOSS AND INCREASE BONE DENSITY AND STRENGTH | SOST, BST2, CALCR | KMT2A 4572/4885POLB 4723/4885MEN1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.